ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
プレスリリース：InnoSerは、重要な生体内および生体外試験サービスを提供し続けています
Press release | Leiden, 19 March 2020InnoSer continues to deliver critical in-vivo and in-vitro services COVID-19 restrictions call for attention to prevent fully halting life sciences operationsInnoSer remains committed to continuing its in-vivo and in-vitro research...
新型コロナウイルス感染症への予防策
Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...
InnoSerとOrganoTherapeutics、中脳オルガノイドの提供を開始
InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...
InnoSerとTheraIndxの戦略的提携
InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...
イノサーが新たな細胞培養施設を導入
InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...
MINDMAPに対するユーロスターズ助成金
53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat...
info@innoserlaboratories.com